Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M

EGFR-Mediated Beclin 1 Phosphorylation in Autophagy Suppression, Tumor Progression, and Tumor Chemoresistance

(2013) Yongjie Wei et al.   CELL

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells

(2013) Yuji Sakuma et al.   LABORATORY INVESTIGATION

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

(2013) Rossana Berardi et al.   OncoTargets and Therapy

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

(2013) A. O. Walter et al.   Cancer Discovery

Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents

(2012) Gang Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

EGFR tyrosine kinase inhibition induces autophagy in cancer cells

(2012) Christopher Fung et al.   CANCER BIOLOGY & THERAPY

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

(2012) Sai-Hong Ignatius Ou   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Recycling of the Epidermal Growth Factor Receptor Is Mediated by a Novel Form of the Clathrin Adaptor Protein Eps15

(2011) Susan Chi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

(2011) Fabrice Pierre et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer

(2011) E. Kwak   ONCOLOGIST

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells

(2011) Weidong Han et al.   PLoS One

CK2 inhibition induces apoptosis via the ER stress response

(2010) Andrea Hessenauer et al.   CELLULAR SIGNALLING

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

(2010) Luis Paz-Ares et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy

(2010) Flavia F. Moreira-Leite et al.   Journal of Thoracic Oncology

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

Protein Kinase CK2 in Health and Disease

(2009) L. A. Pinna et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Protein Kinase CK2 in Health and Disease

(2009) Y. Miyata   CELLULAR AND MOLECULAR LIFE SCIENCES

Protein Kinase CK2 in Health and Disease

(2009) J. H. Trembley et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2009) J. K. Rho et al.   MOLECULAR CANCER RESEARCH

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for Degradation

(2008) Sara Sigismund et al.   DEVELOPMENTAL CELL

Cell cycle and activation of CK2

(2008) Miwako Kato Homma et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA